Nebivolol

Generic Name
Nebivolol
Brand Names
Bystolic
Drug Type
Small Molecule
Chemical Formula
C22H25F2NO4
CAS Number
118457-14-0
Unique Ingredient Identifier
030Y90569U
Background

Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than atenolol, propranolol, or pindolol. Nebivolol and other beta blockers are generally not first l...

Indication

Nebivolol is indicated to treat hypertension.

Associated Conditions
Hypertension
Associated Therapies
-
Clinical Trials
Related News

Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension

Phase 4
Completed
Conditions
Pre-hypertension
Hypertension
Interventions
Drug: Nebivolol
First Posted Date
2010-09-15
Last Posted Date
2019-08-21
Lead Sponsor
University of California, San Diego
Target Recruit Count
50
Registration Number
NCT01202175
Locations
🇺🇸

University of California, San Diego, La Jolla, California, United States

Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Nebivolol
Drug: Metoprolol
First Posted Date
2010-07-05
Last Posted Date
2024-11-06
Lead Sponsor
University of Florida
Target Recruit Count
32
Registration Number
NCT01157234
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

Regulatory Nebilet PMS

Completed
Conditions
Hypertension
Heart Failure
Interventions
Drug: Nebivolol
First Posted Date
2010-03-01
Last Posted Date
2017-05-30
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
743
Registration Number
NCT01077661
Locations
🇰🇷

GSK Investigational Site, Seoul, Korea, Republic of

Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab

Not Applicable
Withdrawn
Conditions
Hypertension
Interventions
Drug: Nebivolol
Drug: Lisinopril
First Posted Date
2010-02-25
Last Posted Date
2012-04-06
Lead Sponsor
University of Mississippi Medical Center
Registration Number
NCT01076140
Locations
🇺🇸

University of Mississippi Medical Center, Jackson, Mississippi, United States

Nebivolol in Patients With Systolic Stage 2 Hypertension

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Placebo
Drug: Nebivolol
First Posted Date
2010-01-27
Last Posted Date
2012-01-11
Lead Sponsor
Forest Laboratories
Target Recruit Count
433
Registration Number
NCT01057251
Locations
🇺🇸

Forest Investigative Site 032, Corpus Christi, Texas, United States

🇺🇸

Forest Investigative Site 009, Atlanta, Georgia, United States

🇺🇸

Forest Investigative Site 038, Baltimore, Maryland, United States

and more 33 locations

Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function

Not Applicable
Completed
Conditions
Hypertension
Interventions
Drug: Nebivolol
First Posted Date
2010-01-26
Last Posted Date
2017-04-18
Lead Sponsor
Mercy Research
Target Recruit Count
53
Registration Number
NCT01056718
Locations
🇺🇸

St. John's Mercy Cardiovascular Research, St. Louis, Missouri, United States

Impact of Nebivolol on Central Aortic Pressure

Not Applicable
Withdrawn
Conditions
Central Aortic Pressure
Interventions
Drug: Nebivolol
Drug: Metoprolol
First Posted Date
2010-01-20
Last Posted Date
2011-08-01
Lead Sponsor
Creighton University
Registration Number
NCT01051947
Locations
🇺🇸

The Cardiac Center at Creighton University, Omaha, Nebraska, United States

The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension

Phase 4
Completed
Conditions
High Blood Pressure
Interventions
Drug: Nebivolol
Drug: Metoprolol XL
First Posted Date
2010-01-14
Last Posted Date
2017-04-11
Lead Sponsor
Emory University
Target Recruit Count
91
Registration Number
NCT01049009
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Nebivolol
Drug: Metoprolol succinate
First Posted Date
2009-12-31
Last Posted Date
2014-12-19
Lead Sponsor
Emory University
Target Recruit Count
96
Registration Number
NCT01041287
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension

Not Applicable
Completed
Conditions
Hypertension
Interventions
Drug: Nebivolol
Drug: Hydrochlorothiazide
First Posted Date
2009-10-22
Last Posted Date
2011-05-05
Lead Sponsor
InVasc Therapeutics, Inc.
Target Recruit Count
40
Registration Number
NCT00999752
Locations
🇺🇸

Atlanta Vascular Research Foundation, Tucker, Georgia, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy